Chronic obstructive pulmonary disease (COPD) is highly prevalent among patients with
atrial fibrillation (AF), shares common risk factors, and adds to the overall morbidity and …

Chronic obstructive pulmonary disease (COPD) is at present the third leading cause of
death in the world. Long-acting muscarinic antagonist (LAMA) is widely used as a …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide; many recent advances have been made in many aspects of the disease. The aim …

Background Myofibroblast differentiation and extracellular matrix (ECM) deposition are
observed in chronic obstructive pulmonary disease (COPD). However, the mechanisms of …

Objective: Fragmented QRS (fQRS) have been reported as a predictor of major adverse
cardiac events (MACE) and mortality in several studies on cardiovascular disease. However …

Objective To evaluate cardiovascular safety of two new inhaled fixed-dose combinations for
treatment of asthma:(i) the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) …

Diagnostic and therapeutic challenges of chronic obstructive... : Current Opinion in
Pulmonary Medicine Diagnostic and therapeutic challenges of chronic obstructive …

Purpose This study aimed to examine reports of cardiovascular adverse events (CV AEs)
observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and …

Background Beta-blocker therapies for cardiovascular comorbidities are often withheld in
patients with chronic obstructive pulmonary disease (COPD) due to potential adverse effects …

Background LABA (long-acting β2-agonists) and/or LAMA (long-acting muscarinic
antagonists) represent the first treatment options for patients with symptomatic COPD …